Figure - PMC

Skip to main content

An official website of the United States government

Here's how you know

Here's how you know

Official websites use .gov
A .gov website belongs to an official government organization in the United States.

Secure .gov websites use HTTPS
A lock ( ) or https:// means you've safely connected to the .gov website. Share sensitive information only on official, secure websites.

View full-text article in PMC

. 2021 Mar 25;14:2177–2183. doi: 10.2147/OTT.S297149

Search in PMC
Search in PubMed
View in NLM Catalog
Add to search

© 2021 Ding et al.

This work is published and licensed by Dove Medical Press Limited. The full terms of this license are available at https://www.dovepress.com/terms.php and incorporate the Creative Commons Attribution – Non Commercial (unported, v3.0) License (http://creativecommons.org/licenses/by-nc/3.0/). By accessing the work you hereby accept the Terms. Non-commercial uses of the work are permitted without any further permission from Dove Medical Press Limited, provided the work is properly attributed. For permission for commercial use of this work, please see paragraphs 4.2 and 5 of our Terms (https://www.dovepress.com/terms.php).

PMC Copyright notice

Abdomen CT scans after 6 months chemotherapy with cisplatin and gemcitabine (A and B) and after 6 cycles of immunotherapy with pembrolizumab (C and D), images on the same sections. (A) Compared with Figure 1A, the patient’s left abdominal aortic lymphadenopathy was enlarged (red arrow). (B) The left main adrenal gland and medial branch nodules were thickened (red arrow), suggesting that the tumor has metastasized. (C) Abdominal aortic lymph node enlargement shrank significantly (red arrow). (D) The left main adrenal nodule disappeared (red arrow), indicating the stabilization of disease progression.